Atea Pharmaceuticals, Inc. Common Stock (AVIR) Stock
Key stats
- Market cap
- $338.88M
- Price / Earnings ratio
- -2.2x
- EPS (TTM)
- -$1.95
- Volume
- Loading
- 52-week high
- $6.45
- 52-week low
- $2.87
Source: third-party data provider, as of November 13, 2026
Compare with AVIR
Recent news

Atea Pharmaceuticals Q2 Earnings Call Highlights
Atea Pharmaceuticals Q2 Earnings Call Highlights
AVIR

Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know
Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know
AVIR

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
AVIR

Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround
Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround
AVIR
Technical indicators
- RSI 14
- 42.37
- MACD 12/26/9
- -0.16
- EMA 9 of MACD
- -0.20
- MACD histogram
- 0.04
- SMA 50
- $4.85
- Price below SMA 50
- EMA 50
- $4.65
- Price below EMA 50
- SMA 200
- $4.95
- Price below SMA 200
- EMA 200
- $4.65
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Atea Pharmaceuticals Q2 Earnings Call Highlights
Atea Pharmaceuticals Q2 Earnings Call Highlights
AVIR

Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know
Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know
AVIR

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
AVIR

Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround
Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround
AVIR

Atea Pharmaceuticals Q1 Earnings Call Highlights
Atea Pharmaceuticals Q1 Earnings Call Highlights
AVIR

New Strong Buy Stocks for October 16th
New Strong Buy Stocks for October 16th
AVIR

Zoom Reports Slowing Growth, but This Stock Is Monday's Real After-Hours Winner
Zoom Reports Slowing Growth, but This Stock Is Monday's Real After-Hours Winner
AVIR
About Atea Pharmaceuticals, Inc. Common Stock
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Jean-Pierre Sommadossi Ph.D. | Founder, Chairman, CEO & President | 1956 |
| Ms. Andrea J. Corcoran J.D. | CFO, Executive VP of Legal & Secretary | 1962 |
| Mr. John F. Vavricka | Chief Commercial Officer | 1963 |
| Dr. Janet M. J. Hammond M.D., Ph.D. | Chief Development Officer | 1960 |
| Dr. Maria Arantxa Horga M.D. | Chief Medical Officer | 1968 |
| Mr. Wayne Foster CPA | Executive VP of Finance & Chief Accounting Officer | 1969 |
| Ms. Jonae R. Barnes | Senior Vice President of Investor Relations & Corporate Communications | — |
| Mr. Adel Moussa Ph.D. | Executive Vice President of Chemistry | — |
| Mr. Xiao-Jian Zhou Ph.D. | Executive Vice President of Early Stage Development | — |
| Mr. Keith Pietropaolo | Executive VP of Clinical Sciences & Project Management | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 42.37
- MACD 12/26/9
- -0.16
- EMA 9 of MACD
- -0.20
- MACD histogram
- 0.04
- SMA 50
- $4.85
- Price below SMA 50
- EMA 50
- $4.65
- Price below EMA 50
- SMA 200
- $4.95
- Price below SMA 200
- EMA 200
- $4.65
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +8.4 | +15.0 | +10.5 | -2.5 | -16.3 | +6.2 | -1.7 | +16.1 | -5.1 | -19.4 | +2.9 |



